Bioventus Inc. $BVS Shares Acquired by Seizert Capital Partners LLC

Seizert Capital Partners LLC increased its position in shares of Bioventus Inc. (NYSE:BVS) by 66.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,758 shares of the company’s stock after acquiring an additional 9,875 shares during the period. Seizert Capital Partners LLC’s holdings in Bioventus were worth $164,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BVS. Russell Investments Group Ltd. boosted its position in shares of Bioventus by 23,761.5% during the 1st quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company’s stock valued at $57,000 after purchasing an additional 6,178 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in Bioventus during the second quarter valued at approximately $72,000. Police & Firemen s Retirement System of New Jersey boosted its holdings in Bioventus by 55.9% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 11,768 shares of the company’s stock worth $78,000 after buying an additional 4,221 shares in the last quarter. PDT Partners LLC acquired a new position in Bioventus in the first quarter worth approximately $120,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Bioventus in the first quarter worth approximately $143,000. 62.94% of the stock is currently owned by institutional investors.

Insider Activity at Bioventus

In other news, Director Michelle Mcmurry-Heath sold 17,701 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $7.42, for a total transaction of $131,341.42. Following the completion of the sale, the director directly owned 56,997 shares of the company’s stock, valued at $422,917.74. This represents a 23.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 33.00% of the stock is currently owned by corporate insiders.

Bioventus Price Performance

Shares of NYSE:BVS opened at $6.72 on Thursday. The company has a market capitalization of $556.17 million, a PE ratio of -11.02 and a beta of 0.80. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The stock has a fifty day moving average of $6.97 and a 200-day moving average of $6.86. Bioventus Inc. has a one year low of $5.81 and a one year high of $12.61.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.